Navigation Links
Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
Date:2/25/2010

BUFFALO, N.Y., Feb. 25 /PRNewswire/ --  Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.  

The study will take place at the University of Chicago, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the University of Wisconsin (Madison), the University of Washington (Seattle) and at Wayne State University. The lead Principal Investigator for the study is Dr. Michael Carducci from Johns Hopkins University.  

The Phase 2 single-arm study will enroll approximately 50 patients with progressive prostate cancer who will receive orally administered KX2-391 twice-daily for 24 weeks.  The primary endpoint of the study is to determine the number of patients who do not have clinical or radiographic progression after 24 weeks of treatment.  Approximately 70% of patients with progressive bone-metastatic prostate cancer who do not undergo treatment, will progress within 24 weeks.  The ability of KX2-391 to improve the outcome of CRPC patients who do not elect to be treated by chemotherapy will be determined.

KX2-391 is an inhibitor of Src kinase signaling and microtubule polymerization and has a broad range of activity in cancer cell lines, including those that are resistant to commonly used chemotherapeutic agents.  Preclinical studies have highlighted the ability of KX2-391 to inhibit the proliferation and metastasis of prostate cancer cell lines in mouse xenografts.

"Based on its mechanism of action and on Phase 1 clinical data, we expect KX2-391 to benefit men with CRPC.  This drug is well tolerated and provides an option for patients who do not want to proceed to chemotherapy," said Dr. Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals.

About Kinex Pharmaceuticals

Kinex is a Buffalo, NY based, privately held biopharmaceutical company committed to the discovery and development of novel therapeutics. The Company's platform technologies, Mimetica™ and Opal™, provide unique insight into the design and synthesis of target-based small molecule inhibitors that selectively act on proteins that play key roles in cancer and immuno-inflammatory diseases.

KX2-391 is currently being studied in a Phase 2 clinical trial in prostate cancer patients; additional Phase 2 oncology studies will commence later in 2010. KX2-361 is being developed for brain cancer; an IND is expected during the 4th quarter of 2010. In addition, Kinex is developing several other new product candidates that inhibit key immuno-inflammatory pathways.

For more information, visit www.kinexpharma.com

SOURCE Kinex Pharmaceuticals

Back to top

RELATED LINKS
http://www.kinexpharma.com

'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
2. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
4. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
5. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
6. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
7. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
8. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
9. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
10. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
11. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
Breaking Medicine News(10 mins):